[1] Martin V, Bettencourt A. Bone regeneration: Biomaterials as local delivery systems with improved osteoinductive properties [J]. Mater Sci Eng C Mater Biol Appl, 2018, 82:363-371.
[2] Shah SR, Werlang CA, Kasper FK, et al. Novel applications of statins for bone regeneration [J]. Natl Sci Rev, 2015, 2(1):85-99.
[3] Petit C, Batool F, Bugueno IM, et al. Contribution of statins towards periodontal treatment: a review [J]. Mediators Inflamm, 2019, 2019:6367402.
[4] Kellesarian SV, Al Amri MD, Al-Kheraif AA, et al. Efficacy of local and systemic statin delivery on the osseointegration of implants: a systematic review [J]. Int J Oral Maxillofac Implants, 2017, 32(3):497-506.
[5] El-Nabarawi N, El-Wakd M, Salem M. Atorvastatin, a double weapon in osteoporosis treatment: an experimental and clinical study [J]. Drug Des Devel Ther, 2017, 11:1383-1391.
[6] Chuang SC, Chen CH, Fu YC, et al. Estrogen receptor mediates simvastatin-stimulated osteogenic effects in bone marrow mesenchymal stem cells [J]. Biochem Pharmacol, 2015, 98(3):453-464.
[7] Shao PL, Wu SC, Lin ZY, et al. Alpha-5 integrin mediates simvastatin-induced osteogenesis of bone marrow mesenchymal stem cells [J]. Int J Mol Sci, 2019, 20(3):506.
[8] Huang Y, Lin Y, Rong M, et al. 20(S)-hydroxycholesterol and simvastatin synergistically enhance osteogenic differentiation of marrow stromal cells and bone regeneration by initiation of Raf/MEK/ERK signaling [J]. J Mater Sci Mater Med, 2019, 30(8): 87.
[9] Xu R, Shi G, Xu L, et al. Simvastatin improves oral implant osseointegration via enhanced autophagy and osteogenesis of BMSCs and inhibited osteoclast activity [J]. J Tissue Eng Regen Med, 2018, 12(5):1209-1219.
[10] Xu R, Chen J, Cong X, et al. Lovastatin protects mesenchymal stem cells against hypoxia-and serum deprivation-induced apoptosis by activation of PI3K/Akt and ERK1/2 [J]. J Cell Biochem, 2008, 103(1): 256-269.
[11] Yang CN, Kok SH, Wang HW, et al. Simvastatin alleviates bone resorption in apical periodontitis possibly by inhibition of mitophagy-related osteoblast apoptosis [J]. Int Endod J, 2019, 52(5):676-688.
[12] Dolci GS, Portela LV, Onofre de Souza D, et al. Atorvastatin-induced osteoclast inhibition reduces orthodontic relapse [J]. Am J Orthod Dentofacial Orthop, 2017, 151(3):528-538.
[13] Dolci GS, Ballarini A, Gameiro GH, et al. Atorvastatin inhibits osteoclastogenesis and arrests tooth movement [J]. Am J Orthod Dentofacial Orthop, 2018, 153(6):872-882.
[14] Gruber R. Cell biology of osteoimmunology [J]. Wien Med Wochenschr, 2010, 160(17-18):438-445.
[15] Ulivieri C, Baldari CT. Statins: from cholesterol-lowering drugs to novel immunomodulators for the treatment of Th17-mediated autoimmune diseases [J]. Pharmacol Res, 2014, 88:41-52.
[16] Toledo AON, Couto AMD, Madeira MFM, et al. Cytokines and chemokines associated with Treg/Th17 response in chronic inflammatory periapical disease [J]. Braz Oral Res, 2019, 33:e093.
[17] Shahbaz SK, Sadeghi M, Koushki K, et al. Regulatory T cells: Possible mediators for the anti-inflammatory action of statins [J]. Pharmacol Res, 2019, 149:104469.
[18] Zhang O, Zhang J. Atorvastatin promotes human monocyte differentiation toward alternative M2 macrophages through p38 mitogen-activated protein kinase-dependent peroxisome proliferator-activated receptor γ activation [J]. Int Immunopharmacol, 2015, 26(1):58-64.
[19] Alhamdi JR, Peng T, Al-Naggar IM, et al. Controlled M1-to-M2 transition of aged macrophages by calcium phosphate coatings [J]. Biomaterials, 2019, 196:90-99.
[20] Spiller KL, Anfang RR, Spiller KJ, et al. The role of macrophage phenotype in vascularization of tissue engineering scaffolds [J]. Biomaterials, 2014, 35(15):4477-4488.
[21] Biswas SK, Chittezhath M, Shalova IN, et al. Macrophage polarization and plasticity in health and disease [J]. Immunol Res, 2012, 53(1-3):11-24.
[22] Koch CA, Krabbe S, Hehmke B. Statins, metformin, proprotein-convertase-subtilisin-kexin type-9 (PCSK9) inhibitors and sex hormones: Immunomodulatory properties? [J]. Rev Endocr Metab Disord, 2018, 19(4):363-395. |
